Nov 12 2015
IRIDEX Corporation today announced its attendance at the 119th annual American Academy of Ophthalmology (AAO) Meeting. The Company will feature its latest product, the Cyclo G6™ laser system equipped with MicroPulse tissue sparing glaucoma technology for the treatment of a range of glaucoma disease states.
This will be the first time the Cyclo G6 will be demonstrated at the AAO Annual Meeting, the industry's foremost conference in vision research and innovation. The Meeting will be held from November 14-17th in Las Vegas.
Glaucoma is a chronic, global disease and the leading cause of adult irreversible blindness. The patient population continues to grow, affecting more than 4 million people in the U.S. and approximately 60 million people worldwide.
Tissue-sparing MicroPulse therapy, which can be performed on the Cyclo G6 via the newly-patented MicroPulse P3 (MP3) probe, is designed to treat patients diagnosed with a range of glaucoma disease states. The Cyclo G6 system includes a glaucoma-dedicated laser along with a family of single use probes, as well as the newly patented MP3 disposable. The Cyclo G6 also offers repeatable and minimally invasive approaches which may slow the progress of the glaucoma.
"We have found that the MicroPulse P3 therapy has the potential to address a significant unmet need in reducing ocular pressure in patients with glaucoma without having to perform an incision," said Nathan M. Radcliffe, M.D., New York Eye Surgery Center. "The technology is easily administered, and often reduces the need for daily eye drop regimens, a considerable improvement for patients who may be prone to missing these critical treatments."
"The MicroPulse system for the treatment of glaucoma along with MicroPulse P3 disposable probes underscore our evolving razor, razorblade business model that focuses on the sale of follow-on disposables that address glaucoma at its early, middle and late stages of development," said William M. Moore, President and Chief Executive Officer of IRIDEX. "It is a safe, cost-effective modality that is also in line with our goal of providing value-based medical technologies."
Source: http://www.iridex.com/